Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DecipHER: HER2- and HER3-Primed Dendritic Cells for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT05504707Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of her2 peptide-pulsed dendritic cells and HER3-primed dendritic cells in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Aug 2022; status: recruiting.
02
Drugs
her2 peptide-pulsed dendritic cellsHER3-primed dendritic cells
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT05504707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504707.